Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Breast 1

Conditions

Sarcoma 1Neurofibrosarcoma 1Neoplasms 1Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × pexidartinib × Clear all
NCT02584647 2025-03-21

PLX3397

Columbia University

Phase 1/2 Terminated
39 enrolled 13 charts
Sarcoma

Sarcoma, Neurofibrosarcoma

NCT01596751 2020-07-17

Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

University of California, San Francisco

Phase 1/2 Completed
67 enrolled 19 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡